Anixa Biosciences ANIX

NASDAQ ANIX

$2.83 -0.07 (-2.41%)

As of: Sep 9, 2026 · 3:59 PM EDT

Key Stats

Market Cap104.14 Mn

P/E-9.96

Div. Yield0.00

Add ratio to table…

About

Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. The company’s therapeutics programs center on a chimeric endocrine receptor‑T cell therapy, a novel CAR‑T approach initially targeting ovarian cancer through its subsidiary Certainty Therapeutics, Inc. Its vaccine programs include a breast cancer vaccine targeting α‑lactalbumin, an ovarian cancer vaccine targeting anti‑Müllerian hormone receptor‑2 extracellular domain, and a vaccine discovery program aimed at identifying retired proteins for lung, colon and prostate cancers. Anixa collaborates with The Wistar Institute, the Cleveland Clinic Foundation, the H. Lee Moffitt Cancer Center and Research Institute, and the National Cancer Institute’s PREVENT program to advance these candidates.

Anixa generates revenue primarily from technology licensing and the sale of patented technologies, including proceeds from litigation settlements. The company has not yet received any revenue from its therapeutic or vaccine candidates, as those programs remain in preclinical and clinical development stages. Limited patent licensing activities constitute a legacy operations component that contributes modestly to overall receipts.

The company operates through the following segments:

Therapeutics: This segment develops chimeric endocrine receptor‑T cell therapy (CAR‑T) for solid tumors, initially ovarian cancer, by engineering T cells to target the follicle‑stimulating hormone receptor; the work is conducted at Certainty Therapeutics in collaboration with Moffitt, and includes ongoing Phase 1 dose‑escalation clinical trials assessing safety, tolerance and early signs of efficacy.
Vaccines: This segment comprises three vaccine initiatives—a breast cancer vaccine targeting α‑lactalbumin, an ovarian cancer vaccine targeting anti‑Müllerian hormone receptor‑2 extracellular domain, and a discovery program seeking retired proteins for lung, colon and prostate cancers; development is carried out with Cleveland Clinic, supported by NCI’s PREVENT program for the ovarian cancer vaccine, and includes Phase 1 clinical trials evaluating safety, immune response and dosing.

Anixa occupies a niche within the competitive oncology biotechnology landscape, where it faces larger pharmaceutical and biotechnology firms as well as academic institutions pursuing similar immuno‑therapy and vaccine approaches. Its competitive advantages stem from proprietary FSH‑Receptor‑directed CAR‑T technology, unique vaccine platforms based on lactation‑associated and menopause‑related proteins, and strategic research alliances with Wistar, Cleveland Clinic, Moffitt and the NCI. These partnerships provide access to cutting‑edge science, clinical trial sites and non‑dilutive funding, helping to offset the resource constraints typical of early‑stage companies.

Anixa’s customers are principally pharmaceutical and biotechnology companies that license its patented technologies or acquire its patent portfolios, as well as research institutions that collaborate on development programs. While specific counterparty names are not disclosed in the filing, the licensing revenue reflects arrangements with entities seeking access to its CAR‑T and vaccine intellectual property.

Investment Thesis

▲ Bull case

Anixa’s breast cancer vaccine has demonstrated a strong biological signal in its Phase 1 trial with safety and tolerability confirmed at the maximum tolerated dose and protocol‑defined immune responses observed in 74% of participants. This level of immunogenicity in a preventive vaccine setting is uncommon for early‑stage oncology programs and suggests the antigen‑targeting approach may be capable of eliciting durable anti‑tumor immunity. The vaccine’s mechanism targets α‑lactalbumin, a protein that is normally silent outside lactation but re‑expressed in many breast cancers, providing a tumor‑selective window that could minimize off‑target effects. Together with the clean safety profile, these data de‑risk the transition to Phase 2 and support the rationale for a neoadjuvant combination study with Keytruda, which could amplify therapeutic benefit and accelerate regulatory pathways. The market may be underestimating the potential for this vaccine to move beyond treatment into true prevention, a space with limited competition and high unmet need.
The company’s ovarian cancer CAR‑T program lira‑cel has shown encouraging survival signals in its ongoing Phase 1 trial despite treatment at doses believed to be suboptimal. Multiple patients have exceeded expected median survival by factors of six to nine, with one individual surviving 28 months and several others remaining alive beyond one year. Importantly, no dose‑limiting toxicities, cytokine release syndrome or neurotoxicity have been observed to date, indicating a favorable safety window that permits aggressive dose escalation under the newly approved protocol amendment allowing up to 100× higher dosing. The addition of lymphodepletion with cyclophosphamide and fludarabine in the next cohort is designed to create a more permissive environment for CAR‑T expansion and persistence, a strategy that has proven pivotal in hematologic malignancies and could translate to solid tumor efficacy. These factors collectively suggest that lira‑cel may possess a clinically meaningful therapeutic index that is not yet reflected in the current valuation.
Anixa’s strategic partnership with Cytovance Biologics for cGMP manufacturing of the breast cancer vaccine material represents a concrete operational milestone that addresses a common bottleneck for early‑stage biotechs. Securing a reliable CDMO capable of producing clinical‑grade material at scale reduces execution risk for the upcoming Phase 2 trial and positions the company to meet potential commercial supply requirements if the vaccine advances. The agreement also signals confidence from an established manufacturing partner in the viability of Anixa’s platform, which could facilitate future collaborations with larger pharmaceutical entities seeking proven production capabilities. By outsourcing complex bioprocessing to a specialist, Anixa can conserve internal resources for preclinical discovery and clinical development, thereby improving capital efficiency. This operational de‑risking is often overlooked by investors focused solely on early clinical data.
The expansion of Anixa’s global intellectual property estate through newly allowed patents in Mexico, Korea and the United States strengthens its defensive moat and enhances its attractiveness as a partner for larger pharma seeking worldwide commercialization rights. Patents extending into the 2040s provide long‑term exclusivity for the breast cancer vaccine platform in key jurisdictions with rising breast cancer incidence and higher rates of triple‑negative disease, markets where preventive strategies could yield substantial commercial value. A robust IP portfolio also improves the company’s leverage in licensing negotiations and reduces the risk of circumvention by competitors. Furthermore, the exclusive license from Cleveland Clinic, coupled with Anixa’s right to retain royalties, creates a predictable revenue stream upon commercialization while preserving upside for shareholders. The market may not be fully pricing in the strategic advantage conferred by this expanding patent shield.
Anixa’s business model of partnering with world‑renowned research institutions such as Moffitt Cancer Center and Cleveland Clinic allows it to leverage cutting‑edge science without bearing the full burden of early‑stage discovery costs. This collaborative approach provides access to preclinical expertise, clinical trial infrastructure and regulatory guidance that would be prohibitively expensive to build in‑house. The company’s ability to continuously scan complementary fields for new technologies creates a pipeline effect where success in one program can catalyze interest and funding for others. Such a model has historically yielded higher capital efficiency and lower cash burn rates for platform‑focused biotechs, potentially extending the runway beyond what peers with internal‑only R&D achieve. Investors focused on near‑term milestones may undervalue the long‑term value generation inherent in this partnership‑driven engine.

Anixa’s breast cancer vaccine has demonstrated a strong biological signal in its Phase 1 trial with safety and tolerability confirmed at the maximum tolerated dose and protocol‑defined immune responses observed in 74% of participants. This level of immunogenicity in a preventive vaccine setting is uncommon for early‑stage oncology programs and suggests the antigen‑targeting approach may be capable of eliciting durable anti‑tumor immunity. The vaccine’s mechanism targets α‑lactalbumin, a protein that is normally silent outside lactation but re‑expressed in many breast cancers, providing a tumor‑selective window that could minimize off‑target effects. Together with the clean safety profile, these data de‑risk the transition to Phase 2 and support the rationale for a neoadjuvant combination study with Keytruda, which could amplify therapeutic benefit and accelerate regulatory pathways. The market may be underestimating the potential for this vaccine to move beyond treatment into true prevention, a space with limited competition and high unmet need.
The company’s ovarian cancer CAR‑T program lira‑cel has shown encouraging survival signals in its ongoing Phase 1 trial despite treatment at doses believed to be suboptimal. Multiple patients have exceeded expected median survival by factors of six to nine, with one individual surviving 28 months and several others remaining alive beyond one year. Importantly, no dose‑limiting toxicities, cytokine release syndrome or neurotoxicity have been observed to date, indicating a favorable safety window that permits aggressive dose escalation under the newly approved protocol amendment allowing up to 100× higher dosing. The addition of lymphodepletion with cyclophosphamide and fludarabine in the next cohort is designed to create a more permissive environment for CAR‑T expansion and persistence, a strategy that has proven pivotal in hematologic malignancies and could translate to solid tumor efficacy. These factors collectively suggest that lira‑cel may possess a clinically meaningful therapeutic index that is not yet reflected in the current valuation.
Anixa’s strategic partnership with Cytovance Biologics for cGMP manufacturing of the breast cancer vaccine material represents a concrete operational milestone that addresses a common bottleneck for early‑stage biotechs. Securing a reliable CDMO capable of producing clinical‑grade material at scale reduces execution risk for the upcoming Phase 2 trial and positions the company to meet potential commercial supply requirements if the vaccine advances. The agreement also signals confidence from an established manufacturing partner in the viability of Anixa’s platform, which could facilitate future collaborations with larger pharmaceutical entities seeking proven production capabilities. By outsourcing complex bioprocessing to a specialist, Anixa can conserve internal resources for preclinical discovery and clinical development, thereby improving capital efficiency. This operational de‑risking is often overlooked by investors focused solely on early clinical data.
The expansion of Anixa’s global intellectual property estate through newly allowed patents in Mexico, Korea and the United States strengthens its defensive moat and enhances its attractiveness as a partner for larger pharma seeking worldwide commercialization rights. Patents extending into the 2040s provide long‑term exclusivity for the breast cancer vaccine platform in key jurisdictions with rising breast cancer incidence and higher rates of triple‑negative disease, markets where preventive strategies could yield substantial commercial value. A robust IP portfolio also improves the company’s leverage in licensing negotiations and reduces the risk of circumvention by competitors. Furthermore, the exclusive license from Cleveland Clinic, coupled with Anixa’s right to retain royalties, creates a predictable revenue stream upon commercialization while preserving upside for shareholders. The market may not be fully pricing in the strategic advantage conferred by this expanding patent shield.
Anixa’s business model of partnering with world‑renowned research institutions such as Moffitt Cancer Center and Cleveland Clinic allows it to leverage cutting‑edge science without bearing the full burden of early‑stage discovery costs. This collaborative approach provides access to preclinical expertise, clinical trial infrastructure and regulatory guidance that would be prohibitively expensive to build in‑house. The company’s ability to continuously scan complementary fields for new technologies creates a pipeline effect where success in one program can catalyze interest and funding for others. Such a model has historically yielded higher capital efficiency and lower cash burn rates for platform‑focused biotechs, potentially extending the runway beyond what peers with internal‑only R&D achieve. Investors focused on near‑term milestones may undervalue the long‑term value generation inherent in this partnership‑driven engine.

▼ Bear case

Despite promising Phase 1 data, Anixa’s breast cancer vaccine remains in early clinical development with no proof of efficacy in preventing tumor recurrence or improving survival in a randomized setting. The 74% immune response rate, while encouraging, does not guarantee clinical benefit, and history shows many cancer vaccines that elicit immune responses fail to translate into meaningful outcomes in Phase 2 or 3 trials. The preventive approach hinges on the assumption that immunizing against α‑lactalbumin will intercept tumor formation before clinical detection, a hypothesis that lacks substantial human data. Moreover, the vaccine’s target is expressed only in a subset of breast cancers, limiting the addressable patient population and potentially reducing commercial scale. Investors may be overestimating the likelihood that this early immunogenicity will survive the heightened scrutiny of later‑stage trials.
The ovarian cancer CAR‑T program lira‑cel, while showing extended survival in a handful of patients, is based on a very small sample size and lacks a control arm, making it difficult to attribute the observed outcomes definitively to the therapy rather than inherent patient variability or concomitant treatments. The trial’s primary objective is safety, and the efficacy signals are anecdotal, which raises the risk that higher dose escalation could uncover unforeseen toxicities not yet apparent at lower doses. Although no dose‑limiting toxicities have been observed, the plan to increase dosing up to 100× the original level introduces substantial uncertainty about safety profiles, especially given the potential for on‑target off‑tumor effects in tissues expressing low levels of FSHR. The reliance on lymphodepletion, a regimen with its own toxicity profile, adds another layer of risk that could offset any gains in CAR‑T activity. The market may be ignoring these safety uncertainties as dose escalation proceeds.
Anixa’s financial position remains dependent on external financing as the company has not yet generated meaningful revenue from its pipeline. Continued reliance on cash‑burning operations will necessitate periodic dilutive financings or strategic partnerships that could alter ownership structure and potentially down‑weight existing shareholders’ upside. The company’s cash runway is not disclosed in the provided news, but the typical burn rate for clinical‑stage biotechs with multiple concurrent programs can be substantial, especially when scaling manufacturing and preparing for Phase 2 trials. Any misstep in trial execution or regulatory feedback could accelerate the need for financing on unfavorable terms. Investors focused solely on promising preclinical or early‑clinical signals may be underestimating the financing risk that accompanies advancement of dual platform programs.
The company’s success is tightly linked to the performance and continued cooperation of its academic partners, Moffitt Cancer Center and Cleveland Clinic. Any disruption in these collaborations—whether due to differing priorities, contractual disagreements, or shifts in institutional strategy—could delay or derail clinical programs. Furthermore, the exclusive licenses from these institutions entail royalty obligations and potential milestones that could erode profitability upon commercialization. Should the partners elect to pursue alternative avenues or license the technology to competitors, Anixa’s competitive advantage could diminish substantially. The market may be assuming that these partnerships will remain stable and favorable throughout the lengthy development timeline, an assumption that may not hold.
The cancer immunotherapy landscape is intensely competitive, with numerous large pharmaceutical companies and specialized biotechs pursuing breast cancer vaccines, CAR‑T therapies and antigen‑targeted approaches. Anixa’s platforms, while scientifically differentiated, face the risk of being overtaken by better‑funded rivals that can advance more rapidly through larger clinical trials, broader manufacturing capabilities and established commercial infrastructures. The preventive vaccine space, in particular, has seen multiple high‑profile failures despite strong preclinical rationales, underscoring the difficulty of translating immunological concepts into population‑level benefit. If competitors achieve regulatory approval first, Anixa could encounter barriers to market entry or be forced into less favorable partnership terms. The market may be overlooking the intensity of competitive pressures that could limit Anixa’s ability to capture significant share even if its technologies succeed.

Despite promising Phase 1 data, Anixa’s breast cancer vaccine remains in early clinical development with no proof of efficacy in preventing tumor recurrence or improving survival in a randomized setting. The 74% immune response rate, while encouraging, does not guarantee clinical benefit, and history shows many cancer vaccines that elicit immune responses fail to translate into meaningful outcomes in Phase 2 or 3 trials. The preventive approach hinges on the assumption that immunizing against α‑lactalbumin will intercept tumor formation before clinical detection, a hypothesis that lacks substantial human data. Moreover, the vaccine’s target is expressed only in a subset of breast cancers, limiting the addressable patient population and potentially reducing commercial scale. Investors may be overestimating the likelihood that this early immunogenicity will survive the heightened scrutiny of later‑stage trials.
The ovarian cancer CAR‑T program lira‑cel, while showing extended survival in a handful of patients, is based on a very small sample size and lacks a control arm, making it difficult to attribute the observed outcomes definitively to the therapy rather than inherent patient variability or concomitant treatments. The trial’s primary objective is safety, and the efficacy signals are anecdotal, which raises the risk that higher dose escalation could uncover unforeseen toxicities not yet apparent at lower doses. Although no dose‑limiting toxicities have been observed, the plan to increase dosing up to 100× the original level introduces substantial uncertainty about safety profiles, especially given the potential for on‑target off‑tumor effects in tissues expressing low levels of FSHR. The reliance on lymphodepletion, a regimen with its own toxicity profile, adds another layer of risk that could offset any gains in CAR‑T activity. The market may be ignoring these safety uncertainties as dose escalation proceeds.
Anixa’s financial position remains dependent on external financing as the company has not yet generated meaningful revenue from its pipeline. Continued reliance on cash‑burning operations will necessitate periodic dilutive financings or strategic partnerships that could alter ownership structure and potentially down‑weight existing shareholders’ upside. The company’s cash runway is not disclosed in the provided news, but the typical burn rate for clinical‑stage biotechs with multiple concurrent programs can be substantial, especially when scaling manufacturing and preparing for Phase 2 trials. Any misstep in trial execution or regulatory feedback could accelerate the need for financing on unfavorable terms. Investors focused solely on promising preclinical or early‑clinical signals may be underestimating the financing risk that accompanies advancement of dual platform programs.
The company’s success is tightly linked to the performance and continued cooperation of its academic partners, Moffitt Cancer Center and Cleveland Clinic. Any disruption in these collaborations—whether due to differing priorities, contractual disagreements, or shifts in institutional strategy—could delay or derail clinical programs. Furthermore, the exclusive licenses from these institutions entail royalty obligations and potential milestones that could erode profitability upon commercialization. Should the partners elect to pursue alternative avenues or license the technology to competitors, Anixa’s competitive advantage could diminish substantially. The market may be assuming that these partnerships will remain stable and favorable throughout the lengthy development timeline, an assumption that may not hold.
The cancer immunotherapy landscape is intensely competitive, with numerous large pharmaceutical companies and specialized biotechs pursuing breast cancer vaccines, CAR‑T therapies and antigen‑targeted approaches. Anixa’s platforms, while scientifically differentiated, face the risk of being overtaken by better‑funded rivals that can advance more rapidly through larger clinical trials, broader manufacturing capabilities and established commercial infrastructures. The preventive vaccine space, in particular, has seen multiple high‑profile failures despite strong preclinical rationales, underscoring the difficulty of translating immunological concepts into population‑level benefit. If competitors achieve regulatory approval first, Anixa could encounter barriers to market entry or be forced into less favorable partnership terms. The market may be overlooking the intensity of competitive pressures that could limit Anixa’s ability to capture significant share even if its technologies succeed.

Segments Breakdown of Revenue (2019)

Peer group

Peer Comparison

Companies in the Gene and Cell Therapy

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	KRYS	Krystal Biotech, Inc.	primary	10.60 Bn	43.81	24.07	-
2	CRSP	CRISPR Therapeutics AG	primary	5.39 Bn	-11.13	402.68	586.20 Mn
3	IOVA	Iovance Biotherapeutics, Inc.	primary	3.98 Bn	-18.93	12.25	-
4	LEGN	Legend Biotech Corp	primary	3.97 Bn	-188.37	3.12	156.40 Mn
5	QURE	uniQure N.V.	primary	3.09 Bn	-14.99	165.24	50.15 Mn
6	BEAM	Beam Therapeutics Inc.	primary	3.06 Bn	-36.22	19.63	112.43 Mn
7	PGEN	Precigen, Inc.	primary	2.54 Bn	-7.53	29.65	93.88 Mn
8	SRPT	Sarepta Therapeutics, Inc.	primary	2.38 Bn	-17.30	1.20	847.62 Mn

Anixa Biosciences ANIX

About

Investment Thesis

Segments Breakdown of Revenue (2019)

Peer Comparison

Create an account

Sign In

Reset Password